Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials
MVMuthiah VaduganathanBCBrian ClaggettPSPardeep S. JhundJWJonathan W. CunninghamJPJoão Pedro Ferreira
Brigham and Women's Hospital · Harvard University · +11 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
640
total citations
- FWCI
- 63.56
- Percentile
- 100%
- References
- 29
Citations per year
Authors
10- MVMuthiah Vaduganathan
Brigham and Women's Hospital, Harvard University
- BCBrian Claggett
Brigham and Women's Hospital, Harvard University
- PSPardeep S. Jhund
University of Glasgow
- JWJonathan W. Cunningham
Brigham and Women's Hospital, Harvard University
- JPJoão Pedro Ferreira
Inserm, Universidade do Porto, Centre d'Investigation Clinique Pierre Drouin, French Clinical Research Infrastructure Network, Défaillance Cardiovasculaire Aiguë et Chronique, Université de Lorraine
Topics & keywords
Topics
Keywords
- Medicine
- Heart failure
- Clinical endpoint
- Ejection fraction
- Hazard ratio
- Internal medicine
- Cardiology
- Combination therapy
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.